Rheumatology Advance Access originally published online on August 2, 2005
Rheumatology 2005 44(12):1473-1482; doi:10.1093/rheumatology/kei012
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
REVIEW |
Disease modification and cardiovascular risk reduction: two sides of the same coin?
1 University of Cambridge School of Medicine, UK and 2 University of Auckland, New Zealand.
Correspondence to: F. C. Hall, ARC Rheumatology Lecturer, Box 157, Level 5, Addenbrooke's Hospital, Cambridge, CB2 2QQ. E-mail: fch22{at}medschl.cam.ac.uk
Inflammatory rheumatic diseases are associated with a substantial increase in accelerated atherosclerosis, with complex interactions between traditional and disease-related risk factors. Therefore, cardiovascular risk reduction should be considered as integral to the control of disease activity in the care plans of patients with RA, SLE and, arguably any chronic inflammatory disease. Shared care structures, already established for the monitoring of DMARDs, could be adapted to communicate and monitor cardiovascular risk reduction objectives. We review the evidence for the efficacy of a range of therapeutic strategies, the majority of which impact on both disease activity and cardiovascular risk. The algorithm proposed here attempts to distil the latest advice from specialist panels at the National Cholesterol Education Program and the British Hypertension Society, as well as incorporating the existing data on SLE and RA patients. The algorithm is structured to minimize clinic time and resources necessary to stratify patients into groups for ROUTINE, SUBSTANTIAL or INTENSIVE risk management; the associated table summarizes optimal therapeutic objectives in each of these groups. The implication of this algorithm is that management of cardiovascular risk should be much more aggressive than is currently the norm in patients with chronic inflammatory diseases, such as RA and SLE. Long-term studies of such interventions are needed to further clarify the benefits of intensive cardiovascular risk management in these patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. I. van Leuven, R. Franssen, J. J. Kastelein, M. Levi, E. S. G. Stroes, and P. P. Tak Systemic inflammation as a risk factor for atherothrombosis Rheumatology, January 1, 2008; 47(1): 3 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. John, E. D. Hale, G. J. Treharne, and G. D. Kitas Patient education on cardiovascular aspects of rheumatoid disease: an unmet need Rheumatology, October 1, 2007; 46(10): 1513 - 1516. [Full Text] [PDF]
|
|
|
|
|
|
A. Young, G. Koduri, M. Batley, E. Kulinskaya, A. Gough, S. Norton, J. Dixey, and on behalf of the Early Rheumatoid Arthritis Study Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis Rheumatology, February 1, 2007; 46(2): 350 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kelly and J. Hamilton What kills patients with rheumatoid arthritis? Rheumatology, February 1, 2007; 46(2): 183 - 184. [Full Text] [PDF]
|
|
|
|
|
|
E. Morrison and H. A. Capell Corticosteroids in the management of early and established rheumatoid disease Rheumatology, September 1, 2006; 45(9): 1058 - 1061. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Armstrong, E. M. McCausland, A. D. Quinn, and G. D. Wright Obesity and cardiovascular risk factors in rheumatoid arthritis Rheumatology, June 1, 2006; 45(6): 782 - 782. [Full Text] [PDF]
|
|